Detroit, MINCT06885281Now EnrollingIRB Ready

Solid Tumors Clinical Trial in Detroit, MI

Access cutting-edge solid tumors treatment through this phase 1/2 clinical trial at a research site in Detroit. Study-provided care at no cost to qualified participants.

Sponsored by Zai Lab (Shanghai) Co., Ltd.

Quick Self-Assessment

See if you qualify for this Detroit location

Preparing your pre-screening questions…

Expert Care in Detroit

Access solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumors treatment provided free

Apply for This Detroit Location

Check if you qualify for this solid tumors clinical trial in Detroit, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Detroit

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Detroit site if eligible
  4. 4Begin participation

About This Solid Tumors Study in Detroit

A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Who Can Participate

Inclusion Criteria

Signed informed consent
Adult men and women ≥18 years of age
Participants must have histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcionomas (NEC)
Participants must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample
Participants must have at least one measurable target lesion as defined by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy ≥ 3 months

Exclusion Criteria

Participants with another known malignancy that is progressing or requires active treatment within the last 2 years
Clinically active central nervous system (CNS) metastases
Participants with leptomeningeal metastasis
Participants who have received any ADC with a payload of topoisomerase I inhibitor (e.g., exatecan derivative)or had received topoisomerase I inhibitor (e.g., irinotecan) as the immediate prior therapy that the participant had progressed from.
Treatment with any systemic anti-cancer treatment or other investigational products/device within 3 weeks before the first dose of study treatment
Non-palliative radiotherapy within 2 weeks to non-thoracic area or within 4 weeks to the thoracic area prior to first dose of study treatment or a history of radiation pneumonitis
Major surgery within 4 weeks of the first dose of study treatment
Hypersensitivity to any ingredient of the study treatment
Out of range value (as defined in protocol) within 10 days prior to the first dose of study treatment
Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment
Lung-specific intercurrent clinically significant illnesses and any autoimmune, connective tissue, or inflammatory disorders including but not limited to pneumonitis
Has a history of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
Pregnant or nursing (lactating) women
Participants who have been on concomitant strong CYP3A or CYP2D6 inhibitors within 14 days or 5 half-lives before the first dose of study treatment, whichever is longer

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Detroit?

Yes, this clinical trial (NCT06885281) has an active research site in Detroit, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumors Treatment Options in Detroit, MI

If you're searching for solid tumors treatment options in Detroit, MI, this clinical trial (NCT06885281) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Detroit research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Detroit, MI

See all advanced solid tumors clinical trials recruiting in Detroit — not just this study.

Browse Advanced Solid Tumors Trials in Detroit →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Detroit?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Detroit, MI